Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZ/su long-term immune persistence and revaccination follow-up in renal transplant recipients
2019-001815-21Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Zoster vaccine recombinant in herpes zoster (HZ), sponsored by GSK. Primary endpoint: Persistence of humoral immunity. Started Sep 2019; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2019-001815-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001815-21.